Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $88
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $77 to $88.
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $77 to $88.